Tower Research Capital LLC (Trc) Eye Point Pharmaceuticals, Inc. Transaction History
Tower Research Capital LLC (Trc)
- $4.87 Billion
- Q4 2024
A detailed history of Tower Research Capital LLC (Trc) transactions in Eye Point Pharmaceuticals, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 4,581 shares of EYPT stock, worth $28,722. This represents 0.0% of its overall portfolio holdings.
Number of Shares
4,581
Previous 9,822
53.36%
Holding current value
$28,722
Previous $78,000
56.41%
% of portfolio
0.0%
Previous 0.0%
Shares
17 transactions
Others Institutions Holding EYPT
# of Institutions
156Shares Held
72.4MCall Options Held
187KPut Options Held
225K-
Cormorant Asset Management, LP Boston, MA8.33MShares$52.2 Million4.9% of portfolio
-
Suvretta Capital Management, LLC New York, NY6.78MShares$42.5 Million2.1% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA5.75MShares$36.1 Million0.08% of portfolio
-
Franklin Resources Inc San Mateo, CA4.14MShares$25.9 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.8MShares$23.8 Million0.0% of portfolio
About EyePoint Pharmaceuticals, Inc.
- Ticker EYPT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 34,072,200
- Market Cap $214M
- Description
- EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intrav...